The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review.

Journal: Brain sciences

Volume: 14

Issue: 3

Year of Publication: 

Affiliated Institutions:  Department of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy. Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. Department of Mental Health and Addictions, ASST Papa Giovanni XXIII, Bergamo, Italy. Department of Mental Health, ASL Lecce, Lecce, Italy. Division of Psychiatry, University of Siena, Siena, Italy. Department of Neurosciences, Mental Health and Sensory Organs, Sant'Andrea Hospital, Sapienza University of Rome, Via di Grottarossa, , Rome, Italy. Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Clinical Psychiatry Unit, Department of Clinical Neurosciences, Università Politecnica delle Marche, Ancona, Italy. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Abstract summary 

Schizophrenia is a severe mental disorder characterized by positive, negative, affective, and cognitive symptoms. Affective symptoms in patients with schizophrenia have traditionally been overlooked or even neglected because they are not considered as fundamental as positive and negative symptoms in the choice of medication.This paper aims to systematically evaluate the efficacy and safety of lurasidone in the treatment of depressive symptoms of schizophrenia.Lurasidone appears to be particularly effective on the depressive symptomatology of schizophrenia while also alleviating the positive and negative symptoms associated with the illness.The efficacy of lurasidone in treating patients with first-episode psychosis who present with predominant depressive symptoms suggests that this medication may be a valuable treatment option not only for established cases of schizophrenia but also for individuals in the early stages of the illness. The good tolerability of lurasidone is an important factor that may positively influence treatment decisions.

Authors & Co-authors:  Fiorillo Sampogna Albert Bondi De Giorgi Fagiolini Pompili Serafini Volpe Vita

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Mesholam-Gately R.I., Johnston D., Keshavan M.S. What’s in the name “schizophrenia”? A clinical, research and lived experience perspective. World Psychiatry. 2023;22:156–157. doi: 10.1002/wps.21033.
Authors :  10
Identifiers
Doi : 225
SSN : 2076-3425
Study Population
Male,Female
Mesh Terms
Other Terms
antipsychotic;depressive symptoms;lurasidone;personalized treatment;schizophrenia
Study Design
Study Approach
Country of Study
Publication Country
Switzerland